Kala Pharmaceuticals (Nasdaq: KALA) filed its S-1/A with the Securities and Exchange Commission for its initial public offering.

The company plans to raise $90M through the offer of 6M shares at a marketed price range of $14 to $16. It also has an additional 900,000 shares as an over-allotment option for its underwriters. Assuming Kala Pharmaceuticals prices at the mid-point of its proposed price range ($15), it would have a market cap value of $350M.

The underwriters for the IPO are BofA Merrill Lynch, Citi, Goldman Sachs, Wells Fargo Securities, Deutsche Bank, J.P. Morgan, Morgan Stanley, Barclays, TPG Capital BD, and JMP Securities

READ FULL ARTICLE HERE